236 related articles for article (PubMed ID: 28124932)
1. [The results of SPRINT study from the point of nephrology].
Monhart V
Vnitr Lek; 2016; 62 Suppl 6():55-57. PubMed ID: 28124932
[TBL] [Abstract][Full Text] [Related]
2. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
[TBL] [Abstract][Full Text] [Related]
3. Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.
Rathi N; Whelton PK; Chertow GM; Cushman WC; Cheung AK; Wei G; Boucher R; Kimmel PL; Bress AP; Kramer HJ; Al-Marji C; Greene T; Beddhu S
Am J Hypertens; 2019 Nov; 32(12):1170-1177. PubMed ID: 31257407
[TBL] [Abstract][Full Text] [Related]
4. SPRINT and the Kidney: What Have We Learned?
Wells R; Rahman M
Curr Hypertens Rep; 2018 Sep; 20(11):95. PubMed ID: 30218213
[TBL] [Abstract][Full Text] [Related]
5. [Managing hypertension in patients with chronic kidney disease - implications of the SPRINT study].
Wojtaszek E; Głogowski T
Wiad Lek; 2016; 69(5):742-744. PubMed ID: 28033599
[TBL] [Abstract][Full Text] [Related]
6. In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?
Tyson CC; Coffman TM
Nephron; 2017; 135(4):287-290. PubMed ID: 28161697
[TBL] [Abstract][Full Text] [Related]
7. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
[TBL] [Abstract][Full Text] [Related]
8. Orthostatic changes in systolic blood pressure among SPRINT participants at baseline.
Townsend RR; Chang TI; Cohen DL; Cushman WC; Evans GW; Glasser SP; Haley WE; Olney C; Oparil S; Del Pinto R; Pisoni R; Taylor AA; Umanath K; Wright JT; Yeboah J;
J Am Soc Hypertens; 2016 Nov; 10(11):847-856. PubMed ID: 27665708
[TBL] [Abstract][Full Text] [Related]
9. Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT).
Agarwal R
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159816
[TBL] [Abstract][Full Text] [Related]
10. Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis.
Rivera M; Tamariz L; Suarez M; Contreras G
Am J Nephrol; 2019; 49(4):297-306. PubMed ID: 30917364
[TBL] [Abstract][Full Text] [Related]
11. Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.
Agarwal A; Wei G; Boucher R; Ahmed F; Beddhu S
Nephrology (Carlton); 2021 Apr; 26(4):303-311. PubMed ID: 33538091
[TBL] [Abstract][Full Text] [Related]
12. How Low Do We Go (in the Post-SPRINT Era)?
Burgner A; Lewis JB
Adv Chronic Kidney Dis; 2019 Mar; 26(2):110-116. PubMed ID: 31023444
[TBL] [Abstract][Full Text] [Related]
13. Aggressive systolic blood pressure control in older subjects: benefits and risks.
Chrysant SG
Postgrad Med; 2018 Mar; 130(2):159-165. PubMed ID: 29375010
[TBL] [Abstract][Full Text] [Related]
14. Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results.
Huang C; Dhruva SS; Coppi AC; Warner F; Li SX; Lin H; Nasir K; Krumholz HM
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29133522
[TBL] [Abstract][Full Text] [Related]
15. A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists.
Rocco MV; Cheung AK
Kidney Int; 2016 Feb; 89(2):261-3. PubMed ID: 26806825
[TBL] [Abstract][Full Text] [Related]
16. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
Egan BM; Li J; Wagner CS
Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
[TBL] [Abstract][Full Text] [Related]
17. Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients.
Aggarwal R; Petrie B; Bala W; Chiu N
Hypertension; 2019 Jun; 73(6):1275-1282. PubMed ID: 31067189
[TBL] [Abstract][Full Text] [Related]
18. Effects of Intensive BP Control in CKD.
Cheung AK; Rahman M; Reboussin DM; Craven TE; Greene T; Kimmel PL; Cushman WC; Hawfield AT; Johnson KC; Lewis CE; Oparil S; Rocco MV; Sink KM; Whelton PK; Wright JT; Basile J; Beddhu S; Bhatt U; Chang TI; Chertow GM; Chonchol M; Freedman BI; Haley W; Ix JH; Katz LA; Killeen AA; Papademetriou V; Ricardo AC; Servilla K; Wall B; Wolfgram D; Yee J;
J Am Soc Nephrol; 2017 Sep; 28(9):2812-2823. PubMed ID: 28642330
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure control in patients with chronic kidney disease.
Lee JY; Han SH
Korean J Intern Med; 2021 Jul; 36(4):780-794. PubMed ID: 34153181
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure control and kidney damage in hypertension: Results of a three-center cross-sectional study in North Central Nigeria.
Abene EE; Gimba ZM; Edah JO; Akinbuwa BA; Uchendu DG; Onyenuche C; Ojo OS; Tzamaloukas AH; Agaba EI
Niger J Clin Pract; 2020 Nov; 23(11):1590-1597. PubMed ID: 33221787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
